25In those circumstances, it must be concluded, as have the Norwegian Government and the Commission, that the detailed and specific requirements regarding the packaging of the medicinal products which are the subject of a central marketing authorisation, which are intended to prevent consumers from being misled and thereby to protect public health, preclude the bundling of the packages of those medicinal products.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.